Depomed (NYSE:ASRT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “Assertio Therapeutics, Inc. is a pharmaceutical company. It develops and markets a product for the treatment in neurology, orphan and diseases of the central nervous system. Assertio Therapeutics, Inc., formerly known as Depomed Inc., is headquartered in Lake Forest, Illinois. “
Other equities research analysts have also issued research reports about the company. Roth Capital reaffirmed a “buy” rating on shares of Depomed in a research report on Tuesday, August 21st. Janney Montgomery Scott downgraded Depomed from a “buy” rating to a “neutral” rating in a report on Wednesday, August 29th.
Depomed (NYSE:ASRT) last posted its quarterly earnings results on Wednesday, August 8th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The business had revenue of $63.27 million during the quarter, compared to the consensus estimate of $63.60 million.
Depomed Company Profile
Assertio Therapeutics, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.
Featured Article: Hedge Funds Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.